December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Mitigation of Corneal Rejection Following Pretreatment With Anti-Icam Oligonucleotide
Author Affiliations & Notes
  • PB Williams
    TR Lee Center for Ocular Pharmacology Eastern Virginia Medical School Norfolk VA
  • NE Alvarez Chedz
    Norfolk VA
  • T Parker
    Norfolk VA
  • A Fateh
    Norfolk VA
  • DA Fellner
    Norfolk VA
  • FA Lattanzio
    Norfolk VA
  • JD Shepard
    Norfolk VA
  • Footnotes
    Commercial Relationships   P.B. Williams, None; N.E. Alvarez Chedz , None; T. Parker , None; A. Fateh , None; D.A. Fellner , None; F.A. Lattanzio, None; J.D. Shepard , None. Grant Identification: Support in part: Lions Med Eye Bank and Res. Ctr. of E. VA
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 135. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      PB Williams, NE Alvarez Chedz, T Parker, A Fateh, DA Fellner, FA Lattanzio, JD Shepard; Mitigation of Corneal Rejection Following Pretreatment With Anti-Icam Oligonucleotide . Invest. Ophthalmol. Vis. Sci. 2002;43(13):135.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Eliminating corneal rejection from corneal transplantation is a highly cost effective endeavor. ISIS 9125 is an anti-sense molecule that inhibits the expression of ICAM-1, an intracellular adhesion molecule. This study assesses the protective effect of corneal donor pretreatment with ISIS 9125. Methods: Corneal allografts (3mm), removed from anesthetized donor ACI rats, were transplanted to anesthetized Lewis rats. Recipients were randomized to no steroids, daily topical steroids, or to incubation in either OptisolTM with ISIS 9125 (400µg/ml), or OptisolTM alone for 24 hr before transplantation. Rejection criteria included cornea opacity, neovascularization, keratic precipitates and conjunctival inflammation. Confocal microscopy was used to document epithelial, stromal and endothelial changes in vivo. Corneas were harvested, after 3d or when rejection criteria were met, and examined by light microscopy (H&E) and scanning electron microscopy. Results: Corneas transplanted immediately after removal from donor rats rejected an average of 5.9 d (range 4-8 d), while those treated with topical steroids lasted an average of 8.4 d (range 6-11 d). The group, whose corneas were incubated in OptisolTM alone for 24 hr, rejected an average of 4.8 d (range 3-7 d). The group, whose corneas were incubated in ISIS 9125 for 24 hr, rejected an average of 6.3 d (range 6-10 d). By day 3, the ISIS 9125 group was graded 50% better than the OptisolTM alone group for corneal opacity and neovascularization. However, the ISIS 9125 group had more corneal edema than the OptisolTM alone group. The scaled data for the corneas harvested on post-op day 3 suggest a trend toward decreased rejection in the ISIS 9125 plus group. Confocal microscopy analysis indicates there is a significant reduction in leukocyte infiltration with use of ISIS 9125. Conclusions: Topical steroids increased days to rejection by 30%, confirming the validity of the transplant model. Incubation with ISIS 9125 increased days to rejection by 25% over OptisolTM alone. Based on these preliminary data, pretreatment of the cornea with ISIS 9125 may reduce the incidence of or delay the onset of rejection reaction, as well as decrease the inflammation associated with the rejection reaction.

Keywords: 471 microscopy: confocal/tunneling • 514 pharmacology • 607 transplantation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.